Grid Therapeutics
Business Services · North Carolina, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
215 Morris St Ste 300, Durham, North Car...Phone Number
(919) 987-7190Website
www.gridtherapeutics.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Grid Therapeutics
Grid Therapeutics is an emerging clinical stage biotechnology company based in Durham, North Carolina, focused on innovating cancer therapy by harnessing the power of the human immune system. The company is dedicated to developing better and safer therapies for cancer, utilizing a unique strategy to create novel tumor-specific therapeutic antibodies from single human B cells. Their target clients include patients and families affected by cancer, as well as investors and partners interested in advancing cancer treatment. Grid Therapeutics is committed to staying at the forefront of research and development in the fight against cancer.Explore more
Grid Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Grid Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Grid Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Grid Therapeutics is spiking on competitors!
Product Launch: Get notified when Grid Therapeutics launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Grid Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Grid Therapeutics
Funding: Get notified immidiatlly once Grid Therapeutics has new funding data
Website visits: Recent activity has been detected on your website
Click to see if Grid Therapeutics had a recent Job posting/layoffs
Earning: See what the market has to say on Grid Therapeutics recently announced quarterly report
Recommended Actions
Reach out to Masked Content who joined Grid Therapeutics as Masked Content
Find 3 more new buyers
Compare Similar Companies to Grid Therapeutics
Compare insights from companies similar to Grid Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Grid Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Grid Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Grid Therapeutics.
Grid Therapeutics Tech Stack
A closer look at the technologies used by Grid Therapeutics
Grid Therapeutics News & Media
Grid Therapeutics Initiates a Phase 2 Investigator-Sponsored Trial of GT103 in Combination with Merck’s Pembrolizumab in Patients with Advanced Stage Non-Small Cell Lung Cancer
DURHAM, N.C.--(BUSINESS WIRE)--Grid Therapeutics Initiates a Phase 2 Investigator-Sponsored Trial of GT103 in Combination with Merck’s Pembrolizumab in Patients with Advanced NSCLCGrid Therapeutics Announces Upcoming Scientific Presentation at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting
DURHAM, N.C.--(BUSINESS WIRE)--Grid Therapeutics Announces Upcoming Scientific Presentation at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual MeetingGrid Therapeutics Announces Enrollment of First Patient in Phase 1 Study of GT103 in Refractory NSCLC Patients
DURHAM, N.C.--(BUSINESS WIRE)--Grid Therapeutics Announces First Patient Enrolled in Phase 1 Study of GT103 in Refractory NSCLC PatientsGrid Therapeutics Announces FDA Approval of IND Application for GT103
DURHAM, N.C.--(BUSINESS WIRE)--Grid Therapeutics Announces FDA Approval of IND Application for GT103. Phase 1 study in refractory NSCLC patients expected to begin in Q2 '2020.
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Grid Therapeutics
Sign Up For FreeTo access detailed company insights
Grid Therapeutics is an emerging clinical stage biotechnology company based in Durham, North Carolina, focused on innovating cancer therapy by harnessing the power of the human immune system. The company is dedicated to developing better and safer therapies for cancer, utilizing a unique strategy to create novel tumor-specific therapeutic antibodie... Read More
